Rajesh Chopra

This inventor holds 14 USPTO granted patents and 15 published patent applications, plus 7 CIPO patents and 1 EPO patent. Top assignees: Celgene Corporation, Signal Pharmaceuticals, Inc.. Active years: 2014-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rajesh Chopra. Retrieved from https://idiyas.com/inventor/rajesh-chopra

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 15)

% Patents Active = 85.7

CIPO Patents = 7 (Patent Applications = 3)

EPO Patents = 1 (Patent Applications = 18)

Average Co-Inventor Count = 3.8

ph-index = 6

Forward Citations = 87(Granted Patents)

Location History:

Summit, NJ (US) (2014 - 2021)
Sutton, GB (2022)

Company Filing History:

Signal Pharmaceuticals, Inc.

patents

Years Active: 2014-2022

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11524950 - Treatment of immune-related and inflammatory diseases (2022-12-13),

2. 11166950 - Treatment of cancer with TOR kinase inhibitors (2021-11-09),

3. 10996215 - Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers (2021-05-04),

4. 10919883 - Treatment of immune-related and inflammatory diseases (2021-02-16),

5. 9937170 - Treatment of cancer with TOR kinase inhibitors (2018-04-10),

6. 9857359 - Methods for determining drug efficacy using cereblon-associated proteins (2018-01-02),

7. 9694015 - Methods for the treatment of locally advanced breast cancer (2017-07-04),

8. 9587281 - Cereblon isoforms and their use as biomarkers for therapeutic treatment (2017-03-07),

9. 9555033 - Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors (2017-01-31),

10. 9493466 - Treatment of cancer with TOR kinase inhibitors (2016-11-15),

11. 9474757 - Methods for treating cancer using TOR kinase inhibitor combination therapy (2016-10-25),

12. 9358232 - Methods for treating cancer using TOR kinase inhibitor combination therapy (2016-06-07),

13. 9119854 - Methods for treating cancer using combination therapy (2015-09-01),

14. 8906932 - Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4Hquinazolin-3-yl)-piperidine-2,6-dione (2014-12-09),

Title: Rajesh Chopra: Innovator in Immunology and Oncology

Introduction

Rajesh Chopra is a prominent inventor based in Summit, NJ (US), known for his significant contributions to the fields of immunology and oncology. With a total of 14 patents, he has developed innovative methods and compositions aimed at treating various immune-related and inflammatory diseases, as well as cancer.

Latest Patents

One of his latest patents focuses on the treatment of immune-related and inflammatory diseases. This patent outlines methods for using compounds and compositions to modulate leukocytic activity, including the activity of B cells, T cells, monocytes, macrophages, and other lymphoid or myeloid-derived cell types. The patent also provides pharmaceutical compositions and dosing regimens for these methods. Another significant patent addresses the treatment of cancer with TOR kinase inhibitors. This invention details methods for treating or preventing solid tumors, non-Hodgkin lymphoma, or multiple myeloma by administering an effective amount of a TOR kinase inhibitor to patients.

Career Highlights

Throughout his career, Rajesh Chopra has worked with notable companies such as Celgene Corporation and Signal Pharmaceuticals, Inc. His work in these organizations has contributed to advancements in therapeutic strategies for complex diseases.

Collaborations

Rajesh has collaborated with several professionals in his field, including Kristen Mae Hege and Anita Gandhi. These collaborations have further enhanced his research and development efforts.

Conclusion

Rajesh Chopra's innovative work in the treatment of immune-related diseases and cancer showcases his dedication to advancing medical science. His numerous patents reflect his commitment to improving patient outcomes through targeted therapies.

Profile summary based on public USPTO records.